Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
286 Leser
Artikel bewerten:
(1)

Mayo Clinic Collaborates With PN Medical on a Research Study of Long COVID Patients

  • The clinical trial aims to identify solutions to combat the respiratory symptoms of post-acute COVID syndrome
  • Participants invited to apply for clinical trial

COCOA BEACH, FL / ACCESSWIRE / October 13, 2021 / PN Medical, a leading developer of cardiopulmonary training devices, is supporting Mayo Clinic in a clinical trial to identify new approaches to treat the symptoms of post-acute COVID syndrome (PACS). The COVID Virtual Recovery Study will focus on people who have tested positive for the SARS-CoV2 infection and have completed a 14-30 day quarantine.

A new study from the University of Oxford reports that more than one-third of COVID-19 patients may experience lingering symptoms for months following infection.1 Commonly referred to as Long COVID, some of the more common symptoms of post-acute COVID syndrome (PACS) include shortness of breath, fatigue, brain fog, loss of taste and smell, joint pain and depression. Health experts say the condition is clearly of public health concern, given the substantial impact it has on society, ranging from increased health care costs to economic and productivity losses.2

The goal of Mayo Clinic's COVID Virtual Recovery Study is to investigate the benefits of respiratory muscle training (RMT) on strengthening the respiratory system and accelerating recovery from COVID-19. The findings will focus on functional recovery, mental wellbeing, and the ability to return to work or to pre-COVID daily activities.

"The respiratory system is central to a number of the lingering symptoms of long COVID," explained Mark A. Carbone, CEO of PN Medical. "Implementing respiratory muscle training can positively impact the pathways involved in breathing and provide a gradual, progressive method to improve respiratory muscle function."

The four-week study is completely virtual, allowing anyone in the U.S. who has been affected by COVID-19 to apply. Participants will receive PN Medical's respiratory muscle training device (THE BREATHER or BREATHER FIT) and follow a training plan on the BREATHER COACH connected app that requires using the device up to two times a day on a specific number of days per week to test its effectiveness in reducing long COVID symptoms.

Interested persons can determine their eligibility and enroll in the COVID Virtual Recovery Study by visiting https://www.pnmedical.com/covid-virtual-recovery-study-cvrs-2/.

"PN Medical shares Mayo Clinic's dedication to evidence-based science and cutting-edge research; in this case to develop drug-free solutions to help people improve their respiratory health," said Carbone. "My hope is that this research study with Mayo Clinic will result in new protocols that lead to COVID resilience before, during and after positive exposure to the virus."

ABOUT PN MEDICAL
PN Medical helps people worldwide improve their respiratory health and performance with a dedication to evidence-based science, cutting-edge research and innovative product and software development. Since 1980, the company has enabled more than 1.5 million people to breathe better, including people who want to decrease the burden of chronic illness or achieve a higher level of human performance without drugs. Respiratory therapist and founder Peggy Nicholson broke new ground with her invention of THE BREATHER, the first respiratory muscle training device of its kind. Endorsed by clinicians worldwide who provide Respiratory Muscle Training (RMT), it is an effective way to treat respiratory, cardiac and neuromuscular impairments. To learn more, visit www.PNMedical.com.

  1. Over a third of COVID-19 patients diagnosed with at least one long-COVID symptom
  2. Long COVID now has a formal definition. Here's what you need to know

Media Contact:
Mark Carbone, CEO, PN Medical, Inc.
mac@pnmedical.com
(407) 310-5302

Editor's note: download images and other assets here.

SOURCE: PN Medical



View source version on accesswire.com:
https://www.accesswire.com/667839/Mayo-Clinic-Collaborates-With-PN-Medical-on-a-Research-Study-of-Long-COVID-Patients

© 2021 ACCESS Newswire
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.